research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
Search
for
Sort by
Research
120-150 / 1000+ results
research Discovery of Autoantigens in the Hair Loss Disorder Alopecia Areata: Implications of Posttranslational Modifications
Scientists are still unsure what triggers the immune system to attack hair follicles in Alopecia areata.
research Treatment Options for Androgenetic Alopecia: Efficacy, Side Effects, Compliance, Financial Considerations, and Ethics
Combination therapies for androgenetic alopecia work best but can have significant side effects and costs.
research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Hair Regrowth in a Patient With Central Centrifugal Cicatricial Alopecia After a 2-Month Trial of Baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Current and Future Pharmacotherapy for Alopecia Areata
New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
research Alopecia Areata: A Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research Emerging Drugs for Alopecia Areata: JAK Inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 NKG2D Lymphocytes in Alopecia Areata Patients
EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Case Report: Alopecia Areata Universalis Successfully Treated with Baricitinib
Baricitinib successfully treated severe hair loss.
research Janus Kinase Inhibitors For Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research Immunopathology and Immunotherapy of Inflammatory Skin Diseases
New targeted immunotherapies are improving treatment for inflammatory skin diseases.
research Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Past, Present, and Future Treatment of Alopecia Areata
More research is needed to find the best long-term treatments for Alopecia Areata.
research Review Article: Dermatological Complications of Immunosuppressive and Anti-TNF Therapy in Inflammatory Bowel Disease
Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
research STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
STAT5 activation is crucial for starting the hair growth phase.
research Costunolide: A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
Costunolide may have multiple health benefits, including promoting hair growth and protecting against cancer and diabetes, but more research is needed.
research Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study
There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
research The Efficacy and Safety of Tofacitinib in Patients with Alopecia Totalis
Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.